Criminal Procedure - Motion to Reduce Duration of Sentence - Eligibility (Vincent Anthony Fisher III Act)
Summary
HB1489 would require the Maryland Medical Assistance Program (Medicaid) to provide comprehensive coverage for the treatment of obesity beginning July 1, 2026. The bill defines that coverage to include intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medications used for chronic weight management in patients with obesity. It also directs the Maryland Department of Health to notify Program recipients about the new coverage requirements.
The bill amends the Health-General Article to add a new Medicaid coverage mandate and to update the list of services the Program must cover. It specifies that coverage criteria for anti-obesity medications may not be more restrictive than the FDA-approved indications, while still allowing the Program to use utilization management to determine medical necessity and appropriateness so long as it is applied in the same manner as for other covered conditions. The bill takes effect October 1, 2025, with the coverage requirement beginning later, on July 1, 2026, and the notice requirement due by June 1, 2026.
Impact
HB1489 would expand mandatory Medicaid benefits in Maryland by adding obesity treatment as a covered service category under the Maryland Medical Assistance Program. It would affect the Department of Health, Medicaid managed care and fee-for-service coverage policies, and providers offering behavioral therapy, bariatric procedures, and anti-obesity drugs. The bill would also create a new statutory section, § 15-157 of the Health-General Article, and amend § 15-103 to incorporate the new coverage mandate into existing Program requirements.
Sentiment
The available record shows no committee transcript, vote tally, or recorded floor debate, and the bill was ultimately withdrawn by the sponsor. Based on the text alone, the measure appears designed as a health coverage expansion aimed at improving access to obesity treatment. Because there is no recorded discussion or vote history, the overall sentiment cannot be measured from legislative debate, but the sponsor’s withdrawal suggests the bill did not advance to a final policy decision.
Contention
The main likely points of contention are the fiscal and administrative costs of mandating comprehensive obesity treatment coverage in Medicaid, including coverage for bariatric surgery and anti-obesity medications. Another potential issue is how strictly the Program may manage utilization and medical necessity, especially for expensive medications, while still complying with the bill’s prohibition on more restrictive coverage criteria than FDA indications. Stakeholders likely to differ include patient advocates and health care providers supporting broader access, versus budget and program administrators concerned about cost, utilization, and implementation.